ArticleLung cancer (Amsterdam, Netherlands)2021

Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer.

Sandra Huicochea Castellanos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.